{"id":754,"date":"2026-01-19T00:00:13","date_gmt":"2026-01-19T08:00:13","guid":{"rendered":"https:\/\/getasecondopinion.ai\/blog\/?p=754"},"modified":"2026-01-19T09:10:55","modified_gmt":"2026-01-19T17:10:55","slug":"fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/","title":{"rendered":"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications"},"content":{"rendered":"\n<p>Glucagon\u2011like peptide\u20111 receptor agonists (GLP\u20111 RAs) have become some of the most widely discussed medications in recent years &#8211; largely because of their role in weight loss and diabetes management. Drugs like <a href=\"https:\/\/www.getasecondopinion.ai\/medication\/wegovy\">Wegovy<\/a>, <a href=\"https:\/\/www.getasecondopinion.ai\/medication\/saxenda\">Saxenda<\/a>, and <a href=\"https:\/\/www.getasecondopinion.ai\/medication\/zepbound\">Zepbound<\/a> have helped millions of people manage obesity and improve metabolic health.<\/p>\n\n\n\n<p>But until recently, these medications carried a warning about a <em>possible<\/em> risk of suicidal thoughts or behaviors. That warning created confusion, fear, and hesitation for many people considering these treatments.<\/p>\n\n\n\n<p>In January 2026, the U.S. Food and Drug Administration (FDA) announced a major update: the agency is requesting that drug manufacturers remove the suicidal ideation and behavior warning from GLP\u20111 RA labels after completing a large, multi\u2011year safety review.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>Why Did the FDA Request This Label Change?<\/strong><\/h1>\n\n\n\n<p>For years, GLP\u20111 RA medications included a precaution about the potential risk of suicidal thoughts or behaviors. This warning was originally added out of caution, not because a clear link had been proven.<\/p>\n\n\n\n<p>In 2023, after receiving scattered post\u2011marketing reports, the FDA launched a formal investigation. Over the next two years, the agency conducted:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A meta\u2011analysis of 91 clinical trials involving more than 100,000 patients<\/li>\n\n\n\n<li>A retrospective cohort study using national healthcare claims data<\/li>\n\n\n\n<li>A review of observational studies and published research<\/li>\n\n\n\n<li>A comparison of GLP\u20111 RA users with users of other diabetes medications<\/li>\n<\/ul>\n\n\n\n<p>Across all of these analyses, the FDA found no increased risk of suicidal ideation or behavior among people taking GLP\u20111 RAs.<\/p>\n\n\n\n<p>This conclusion was consistent across multiple independent studies and international regulatory reviews.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>What the FDA Found: A Simple Breakdown<\/strong><\/h1>\n\n\n\n<p>To make this easier to understand, here\u2019s a plain\u2011language summary of the FDA\u2019s findings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>1. No Increased Risk in Clinical Trials<\/strong><\/h2>\n\n\n\n<p>The FDA reviewed 91 clinical trials involving 107,910 participants.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>60,338 received a GLP\u20111 RA<\/li>\n\n\n\n<li>47,572 received a placebo<\/li>\n<\/ul>\n\n\n\n<p><strong>Result:<\/strong>&nbsp;&nbsp;There was <em>no difference<\/em> in suicidal thoughts or behaviors between the two groups.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>2. No Increased Risk in Real\u2011World Data<\/strong><\/h2>\n\n\n\n<p>The FDA analyzed healthcare claims from over 2.2 million adults.<\/p>\n\n\n\n<p>They compared people taking GLP\u20111 RAs with those taking SGLT2 inhibitors (another diabetes drug class).<\/p>\n\n\n\n<p><strong>Result:<\/strong>&nbsp;No increased risk of intentional self\u2011harm in GLP\u20111 RA users.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>3. No Increased Risk in Subgroups<\/strong><\/h2>\n\n\n\n<p>The FDA also looked at:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adults with obesity<\/li>\n\n\n\n<li>Adults with type 2 diabetes<\/li>\n\n\n\n<li>Adolescents using GLP\u20111 RAs<\/li>\n<\/ul>\n\n\n\n<p><strong>Result:<\/strong>&nbsp;&nbsp;Still no increased risk. Some studies even suggested a <em>lower<\/em> risk of suicidal ideation among GLP\u20111 RA users.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>4. International Agencies Found the Same<\/strong><\/h2>\n\n\n\n<p>The UK\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) also found <strong>no link<\/strong> between GLP\u20111 RAs and suicidal behavior.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>Why Was There a Warning in the First Place?<\/strong><\/h1>\n\n\n\n<p>When GLP\u20111 RAs were first approved, the FDA added the warning out of caution because:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Older weight\u2011loss medications had been associated with psychiatric side effects<\/li>\n\n\n\n<li>A few isolated reports mentioned mood changes<\/li>\n\n\n\n<li>Obesity itself is linked to higher rates of depression, making it hard to separate cause and effect<\/li>\n<\/ul>\n\n\n\n<p>This is a common regulatory practice: \u201cbetter safe than sorry\u201d until more data becomes available.<\/p>\n\n\n\n<p>Now, after years of research, the FDA has enough evidence to confidently say the warning is not supported by the data.<\/p>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;background-color:#fff6eb;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/10\/cta-background-02.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-9d2deb30 wp-block-group-is-layout-constrained\" style=\"padding-top:0px;padding-right:0px;padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-e1a2b4d20c009cbe1ac01729b645a8a1\">Experiencing Side Effects? <br>Let\u2019s Rethink Your Meds.<\/h3>\n\n\n\n<p>Explore treatment options that may work better for your body &#8211; with fewer side effects and lower costs. It\u2019s fast, free, and tailored to you. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>Which Medications Are Affected?<\/strong><\/h1>\n\n\n\n<p>The FDA\u2019s request applies to GLP\u20111 RAs approved for weight loss, including:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Medication<\/strong><\/td><td><strong>Generic Name<\/strong><\/td><td><strong>Manufacturer<\/strong><\/td><td><strong>Indication<\/strong><\/td><\/tr><tr><td><a href=\"https:\/\/www.getasecondopinion.ai\/medication\/wegovy\">Wegovy<\/a><\/td><td><a href=\"https:\/\/www.getasecondopinion.ai\/medication\/semaglutide\">Semaglutide<\/a><\/td><td>Novo Nordisk<\/td><td>Weight loss<\/td><\/tr><tr><td><a href=\"https:\/\/www.getasecondopinion.ai\/medication\/saxenda\">Saxenda<\/a><\/td><td><a href=\"https:\/\/www.getasecondopinion.ai\/medication\/liraglutide\">Liraglutide<\/a><\/td><td>Novo Nordisk<\/td><td>Weight loss<\/td><\/tr><tr><td><a href=\"https:\/\/www.getasecondopinion.ai\/medication\/zepbound\">Zepbound<\/a><\/td><td><a href=\"https:\/\/www.getasecondopinion.ai\/medication\/tirzepatide\">Tirzepatide<\/a><\/td><td>Eli Lilly<\/td><td>Weight loss<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Important:<\/strong>&nbsp;GLP\u20111 RAs approved <em>only<\/em> for type 2 diabetes never included this warning and are not affected by the change.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>What Are GLP\u20111 RA Medications, in Simple Terms?<\/strong><\/h1>\n\n\n\n<p>GLP\u20111 RAs mimic a natural hormone your body releases after you eat. They help:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reduce appetite<\/li>\n\n\n\n<li>Slow digestion<\/li>\n\n\n\n<li>Lower blood sugar<\/li>\n\n\n\n<li>Support weight loss<\/li>\n<\/ul>\n\n\n\n<p>They are not psychiatric medications, and they do not act on the brain in ways associated with depression or suicidal thoughts.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>What Should Patients and Caregivers Do Now?<\/strong><\/h1>\n\n\n\n<p>The FDA\u2019s updated guidance is clear:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>There is no evidence that GLP\u20111 RAs increase suicidal thoughts or behaviors.<\/li>\n\n\n\n<li>Patients should not stop their medication without talking to their doctor.<\/li>\n\n\n\n<li>Caregivers should continue to monitor mood changes, just as they would with any major health treatment.<\/li>\n<\/ul>\n\n\n\n<p>The FDA emphasizes that people should feel reassured by the updated evidence.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>What the Evidence Shows<\/strong><\/h1>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Question<\/strong><\/td><td><strong>What the Evidence Says<\/strong><\/td><\/tr><tr><td>Do GLP\u20111 RAs increase suicidal thoughts?<\/td><td>No. Large trials and real\u2011world data show no increased risk.<\/td><\/tr><tr><td>Did the FDA investigate thoroughly?<\/td><td>Yes. 91 trials + 2.2M\u2011person claims study + observational research.<\/td><\/tr><tr><td>Are weight\u2011loss GLP\u20111 RAs affected?<\/td><td>Yes. Wegovy, Saxenda, Zepbound.<\/td><\/tr><tr><td>Are diabetes\u2011only GLP\u20111 RAs affected?<\/td><td>No. They never carried this warning.<\/td><\/tr><tr><td>Should patients stop taking their medication?<\/td><td>No. Continue as prescribed unless advised otherwise.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>Why This Matters for Public Health<\/strong><\/h1>\n\n\n\n<p>Removing this warning helps:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1. Reduce unnecessary fear<\/strong><\/h3>\n\n\n\n<p>Many people avoided GLP\u20111 RAs because of the warning, even though the risk was never proven.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2. Improve access to effective treatments<\/strong><\/h3>\n\n\n\n<p>Obesity is a chronic disease, and GLP\u20111 RAs have been shown to help with weight loss and metabolic health.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3. Ensure consistent, accurate labeling<\/strong><\/h3>\n\n\n\n<p>The FDA wants all GLP\u20111 RA labels to reflect the same scientific evidence.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>4. Support informed decision\u2011making<\/strong><\/h3>\n\n\n\n<p>Patients deserve clear, evidence\u2011based information &#8211; not outdated warnings.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>What Drugmakers Are Saying<\/strong><\/h1>\n\n\n\n<p>Both Novo Nordisk and Eli Lilly publicly supported the FDA\u2019s decision:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Novo Nordisk said it is \u201chappy to see the FDA\u2019s recommendation\u201d and emphasized its commitment to patient safety.<\/li>\n\n\n\n<li>Eli Lilly stated that patient safety remains its top priority and that it will work with the FDA on next steps.<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>What This Means for You<\/strong><\/h1>\n\n\n\n<p>If you or someone you care about is using a GLP\u20111 RA medication &#8211; or considering one &#8211; this update should provide reassurance. The FDA\u2019s decision is based on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The largest and most comprehensive data review to date<\/li>\n\n\n\n<li>Consistent findings across multiple types of studies<\/li>\n\n\n\n<li>International agreement from other regulatory agencies<\/li>\n<\/ul>\n\n\n\n<p>In short: GLP\u20111 RAs do not increase the risk of suicidal thoughts or behaviors.<\/p>\n\n\n\n<p>But as with any medication, it\u2019s important to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Stay in communication with your healthcare provider<\/li>\n\n\n\n<li>Report any unusual mood changes<\/li>\n\n\n\n<li>Follow dosing instructions carefully<\/li>\n\n\n\n<li>Avoid stopping medication abruptly<\/li>\n<\/ul>\n\n\n\n<div class=\"wp-block-group unauthenticated invisible has-global-padding is-layout-constrained wp-container-core-group-is-layout-675f737c wp-block-group-is-layout-constrained\" style=\"padding-right:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30)\">\n<div class=\"wp-block-group cta-background has-custom-off-white-background-color has-background has-global-padding is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-64f51f8a wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-radius:30px;padding-top:var(--wp--preset--spacing--30);padding-right:var(--wp--preset--spacing--30);padding-bottom:var(--wp--preset--spacing--30);padding-left:var(--wp--preset--spacing--30);box-shadow:var(--wp--preset--shadow--natural);background-image:url(&apos;https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/cta-background-01.webp&apos;);background-position:100% 100%;background-repeat:no-repeat;background-size:contain;background-attachment:scroll;\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-153751c2 wp-block-group-is-layout-constrained\" style=\"padding-bottom:10px\">\n<h3 class=\"wp-block-heading has-text-align-center has-accent-1-color has-text-color has-link-color has-large-font-size wp-elements-b6fe6b9c1e90c3ca0e3d22a4a0e21d9e\">Better Treatment, Lower Cost &#8211; No Catch.<\/h3>\n\n\n\n<p>Find safer, more effective medications with fewer side effects &#8211; often for less money. It\u2019s fast, free, and personalized. <strong><a href=\"https:\/\/getasecondopinion.ai\/intro-summary\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Sources (4)<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>\u00a0FDA Drug Safety Communication \u2013 <em>FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP\u20111 RA Medications<\/em><\/strong><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/drugmakers-welcome-fdas-glp-1ra-suicide-warning-removal-request\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Pharmaceutical Technology \u2013 <em>Drugmakers welcome FDA\u2019s GLP\u20111RA suicide warning removal request<\/em><\/strong><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.healio.com\/news\/endocrinology\/20260114\/fda-asks-for-removal-of-suicidal-ideation-risk-from-glp1-labels-following-investigation\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Healio \u2013 <em>FDA asks for removal of suicidal ideation risk from GLP\u20111\u00a0<\/em><\/strong><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.biospace.com\/fda\/fda-asks-novo-lilly-to-remove-suicide-warnings-from-glp-1-weight-loss-products\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>BioSpace \u2013 <em>FDA Asks Novo, Lilly To Remove Suicide Warnings From GLP\u20111 Weight Loss Products<\/em><\/strong><\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Glucagon\u2011like peptide\u20111 receptor agonists (GLP\u20111 RAs) have become some of the most widely discussed medications in recent years &#8211; largely because of their role in weight loss and diabetes management. Drugs like Wegovy, Saxenda, and Zepbound have helped millions of people manage obesity and improve metabolic health. But until recently, these medications carried a warning [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":755,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[552,547,548,544,551,549,546,550,543,545],"class_list":["post-754","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fda-updates","tag-diabetes-medication-news","tag-fda-label-update","tag-glp-1-ra-medications","tag-saxenda-safety","tag-semaglutide-safety","tag-suicidal-ideation-risk","tag-tirzepatide-fda-decision","tag-wegovy-news","tag-weight-loss-drugs","tag-zepbound-warning-removal"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications - Get a Second Opinion<\/title>\n<meta name=\"description\" content=\"FDA finds no link to suicide risk in GLP-1 meds, requests warning removal from Wegovy, Saxenda, and Zepbound labels.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications - Get a Second Opinion\" \/>\n<meta property=\"og:description\" content=\"FDA finds no link to suicide risk in GLP-1 meds, requests warning removal from Wegovy, Saxenda, and Zepbound labels.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/\" \/>\n<meta property=\"og:site_name\" content=\"Get a Second Opinion\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/getasecondopinion\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T08:00:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T17:10:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/01\/GLP-Suicide-Removal.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"G2O\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G2O\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/\"},\"author\":{\"name\":\"G2O\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\"},\"headline\":\"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications\",\"datePublished\":\"2026-01-19T08:00:13+00:00\",\"dateModified\":\"2026-01-19T17:10:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/\"},\"wordCount\":1075,\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/GLP-Suicide-Removal.jpg\",\"keywords\":[\"diabetes medication news\",\"FDA label update\",\"GLP-1 RA medications\",\"Saxenda safety\",\"semaglutide safety\",\"suicidal ideation risk\",\"tirzepatide FDA decision\",\"Wegovy news\",\"weight loss drugs\",\"Zepbound warning removal\"],\"articleSection\":[\"FDA Updates\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/\",\"name\":\"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications - Get a Second Opinion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/GLP-Suicide-Removal.jpg\",\"datePublished\":\"2026-01-19T08:00:13+00:00\",\"dateModified\":\"2026-01-19T17:10:55+00:00\",\"description\":\"FDA finds no link to suicide risk in GLP-1 meds, requests warning removal from Wegovy, Saxenda, and Zepbound labels.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/GLP-Suicide-Removal.jpg\",\"contentUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/GLP-Suicide-Removal.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Professional medical header image showing a Wegovy box, GLP-1 injection pen, and blister pack of tablets, with bold headline text reading \u201cFDA Requests Removal of Suicidal Behavior Warning from GLP-1 RA Medications\u201d clearly displayed on a blue overlay.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/policy-alerts\\\/fda-updates\\\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Insights\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Policy Alerts\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/policy-alerts\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA Updates\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/policy-alerts\\\/fda-updates\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"name\":\"Get a Second Opinion\",\"description\":\"Insights\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\",\"name\":\"Get a Second Opinion\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"contentUrl\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"width\":1000,\"height\":129,\"caption\":\"Get a Second Opinion\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/getasecondopinion\",\"https:\\\/\\\/www.instagram.com\\\/getasecondopinion\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\",\"name\":\"G2O\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"caption\":\"G2O\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications - Get a Second Opinion","description":"FDA finds no link to suicide risk in GLP-1 meds, requests warning removal from Wegovy, Saxenda, and Zepbound labels.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/","og_locale":"en_US","og_type":"article","og_title":"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications - Get a Second Opinion","og_description":"FDA finds no link to suicide risk in GLP-1 meds, requests warning removal from Wegovy, Saxenda, and Zepbound labels.","og_url":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/","og_site_name":"Get a Second Opinion","article_publisher":"https:\/\/www.facebook.com\/getasecondopinion","article_published_time":"2026-01-19T08:00:13+00:00","article_modified_time":"2026-01-19T17:10:55+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/01\/GLP-Suicide-Removal.jpg","type":"image\/jpeg"}],"author":"G2O","twitter_card":"summary_large_image","twitter_misc":{"Written by":"G2O","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/#article","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/"},"author":{"name":"G2O","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20"},"headline":"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications","datePublished":"2026-01-19T08:00:13+00:00","dateModified":"2026-01-19T17:10:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/"},"wordCount":1075,"publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/01\/GLP-Suicide-Removal.jpg","keywords":["diabetes medication news","FDA label update","GLP-1 RA medications","Saxenda safety","semaglutide safety","suicidal ideation risk","tirzepatide FDA decision","Wegovy news","weight loss drugs","Zepbound warning removal"],"articleSection":["FDA Updates"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/","url":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/","name":"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications - Get a Second Opinion","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/#primaryimage"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/01\/GLP-Suicide-Removal.jpg","datePublished":"2026-01-19T08:00:13+00:00","dateModified":"2026-01-19T17:10:55+00:00","description":"FDA finds no link to suicide risk in GLP-1 meds, requests warning removal from Wegovy, Saxenda, and Zepbound labels.","breadcrumb":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/#primaryimage","url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/01\/GLP-Suicide-Removal.jpg","contentUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2026\/01\/GLP-Suicide-Removal.jpg","width":1536,"height":1024,"caption":"Professional medical header image showing a Wegovy box, GLP-1 injection pen, and blister pack of tablets, with bold headline text reading \u201cFDA Requests Removal of Suicidal Behavior Warning from GLP-1 RA Medications\u201d clearly displayed on a blue overlay."},{"@type":"BreadcrumbList","@id":"https:\/\/www.getasecondopinion.ai\/blog\/policy-alerts\/fda-updates\/fda-requests-removal-of-suicidal-behavior-warning-from-glp-1-medications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Insights","item":"https:\/\/www.getasecondopinion.ai\/blog\/"},{"@type":"ListItem","position":2,"name":"Policy Alerts","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/policy-alerts\/"},{"@type":"ListItem","position":3,"name":"FDA Updates","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/policy-alerts\/fda-updates\/"},{"@type":"ListItem","position":4,"name":"FDA Requests Removal of Suicidal Behavior Warning from GLP\u20111 Medications"}]},{"@type":"WebSite","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website","url":"https:\/\/www.getasecondopinion.ai\/blog\/","name":"Get a Second Opinion","description":"Insights","publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization","name":"Get a Second Opinion","url":"https:\/\/www.getasecondopinion.ai\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","contentUrl":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","width":1000,"height":129,"caption":"Get a Second Opinion"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/getasecondopinion","https:\/\/www.instagram.com\/getasecondopinion"]},{"@type":"Person","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20","name":"G2O","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","caption":"G2O"}}]}},"_links":{"self":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/comments?post=754"}],"version-history":[{"count":5,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/754\/revisions"}],"predecessor-version":[{"id":764,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/754\/revisions\/764"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media\/755"}],"wp:attachment":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media?parent=754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/categories?post=754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/tags?post=754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}